Zoetis (NYSE:ZTS) Hits New 12-Month Low Following Analyst Downgrade

Zoetis Inc. (NYSE:ZTS) reached a new 52-week low during trading on Tuesday after TD Cowen lowered their price target on the stock from $150.00 to $104.00. TD Cowen currently has a buy rating on the stock. Zoetis traded as low as $72.03 and last traded at $72.3490, with a volume of 413453 shares. The stock had previously closed at $73.25.

Several other research analysts have also issued reports on ZTS. William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Morgan Stanley restated an “overweight” rating and set a $115.00 price objective on shares of Zoetis in a report on Friday, May 15th. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $130.85.

Insider Buying and Selling at Zoetis

In other news, Director Paul Bisaro bought 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the purchase, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael B. Mccallister bought 3,000 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director owned 24,524 shares of the company’s stock, valued at $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have purchased 11,650 shares of company stock worth $886,384. Corporate insiders own 0.22% of the company’s stock.

Hedge Funds Weigh In On Zoetis

Hedge funds have recently modified their holdings of the company. Global Wealth Strategies & Associates purchased a new stake in shares of Zoetis during the fourth quarter valued at approximately $25,000. Prosperity Bancshares Inc purchased a new position in Zoetis in the fourth quarter worth $25,000. KERR FINANCIAL PLANNING Corp purchased a new position in Zoetis in the third quarter worth $31,000. Cassaday & Co Wealth Management LLC bought a new position in Zoetis in the 1st quarter valued at $28,000. Finally, Lodestone Wealth Management LLC bought a new position in Zoetis in the 4th quarter valued at $30,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 1.4%

The stock has a market capitalization of $30.26 billion, a PE ratio of 11.97, a price-to-earnings-growth ratio of 1.19 and a beta of 0.75. The firm has a 50-day moving average price of $87.78 and a 200-day moving average price of $110.59. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.Zoetis’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period last year, the firm posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is currently 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.